Latest Regulatory Filings News

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Orthocell Limited has reported a record half-year revenue of $6.2 million, driven by accelerating sales of its regenerative medicine products and expanding global footprint. The company’s US commercial launch of Remplir™ is gaining momentum alongside new market entries in Canada, Hong Kong, and Europe.

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

TZ Limited has amended its Appendix 4C for the December 2025 quarter, clarifying cash flow details and signalling improved operating cash flows ahead. The company also updates its funding arrangements, including loan repayments and a proposed trade finance facility.

Big gains hit wealth platforms while Zip swung the other way as early optimism didn’t stick. Dividends and buy-backs kept coming, but investors still punished stocks where the next step looks unclear.

Celsius Resources has appointed Peter Hume as interim chairman while progressing the sale of its Opuwo project and reclaiming a key 60% shareholding in its Philippine affiliate after funding obligations were unmet.

Klevo Rewards Ltd has responded to ASX concerns over a delayed director interest disclosure, attributing the lapse to administrative timing issues and pledging enhanced compliance measures.

BPH Energy Ltd reported a half-year net loss of $925,691, weighed down by investment write-downs and associate losses, while raising $1.2 million to fund exploration and development. The company’s future hinges on a Federal Court review of a critical offshore permit held by investee Advent Energy.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Kali Metals Limited has successfully raised approximately A$7 million through a Tranche 1 Placement, issuing over 38 million new shares at 18 cents each. This capital injection marks a significant step in the company’s funding strategy.

Native Mineral Resources has successfully poured 1,543 ounces of gold doré at its Blackjack Processing Plant, while progressing key operational and regulatory initiatives to optimise mining and processing activities.